YTHDF2 deficiency in DCs potentiates RT. (A) MC38 tumor growth curves in WT mice or Ythdf2-cKO mice with or without IR treatment (20 Gy). 1 million tumor cells were injected s.c., and tumors were irradiated when sizes reached around 120 mm³ (on day 12) (n = 5, mean ± SD). (B) LLC tumor growth curves in WT or Ythdf2-cKO mice with or without IR treatment (20 Gy). 1 million tumor cells were injected s.c., and tumors were irradiated when sizes reached around 100 mm³ (day 10 after implantation) (n = 5, mean ± SD). (C) H&E staining of lungs of LLC tumor–bearing mice 30 days after tumor inoculation; scale bars: 2 mm. Treatments are as indicated in B. (D) Quantification of total area of metastasis in lungs of C, using QuPath (n = 5, mean ± SEM). (E) CT images of mice at different time points (red color indicating tumor area) and representative calculated tumor contours (green) on day 25. KPC tumor cells were injected orthotopically in the pancreas. IR treatment (6 Gy dose) was delivered guided by CT imaging on day 11. (F) Growth curves of orthotopic KPC tumors in WT or Ythdf2-cKO mice with or without IR treatment (n = 5, mean ± SD). Statistical analysis was performed using two-sided unpaired Student’s t test (A, B, D, and F); ***P < 0.001. H&E, hematoxylin and eosin; s.c., subcutaneously.